A site designed to take the mystery out of biopharm equipment selection, GMP concepts and good engineering practice.
The GMPs and good engineering practice
Alfa Laval has launched a new biopharm portal at www.alfalaval.com/biopharm. Designed to take the mystery out of biopharm equipment selection, the site explains underlying GMP concepts and shows how these are applied in Alfa Laval’s own product design. An introductory film can be viewed at YouTube or Alfa Laval’s biopharm portal.
Alfa Laval, the supplier behind world-renowned separation systems and the well-known Tri-Clover and Toftejorg brands, is sharing equipment insights with the biopharm industry, which can help in avoiding the pitfalls of equipment selection.
“Becoming familiar with the ideas behind the GMPs is one of the best ways for a biopharm company to save both time and money,” says Per-Åke Ohlsson, head of Alfa Laval’s Market Unit Pharma Equipment. “Although the GMPs are not specific answers to specific problems, they do contain general principles that lead to optimal solutions if understood and applied correctly.”
From theory to practice
The website focus on the key areas of performance, documentation and hygiene, explaining how even small differences in the design or manufacture of equipment can have far-reaching consequences for validation and subsequent biopharm production.
Take 3 minutes to view an introductory film:
www.alfalaval.com/biopharm
or on YouTube.
Contact
Contact details to Alfa Laval sales companies around the world can be found at www.alfalaval.com/biopharm
Per-Åke Ohlsson, head of Alfa Laval’s Market unit Pharma
Phone: +46 46 36 70 00
E-mail: ref="mailto:perake.ohlsson@alfalaval.com">perake.ohlsson@alfalaval.com
Biopharm portal site: www.alfalaval.com/biopharm
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.